Ledipasvir/Tegobuvir/Vedroprevir + Rosuvastatin = Prohibited

Effect on Concentration

Ledipasvir/Tegobuvir/Vedroprevir
Unknown
Applies within class?
No
Rosuvastatin
Increase
Applies within class?
No

Pharmacologic Effects

Ledipasvir/Tegobuvir/Vedroprevir
Effect
N/A
Applies within class?
No
Rosuvastatin
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 22-Nov-2022

Summary

Sources

ledipasvir/sofosbuvir vs pravastatin, rosuvastatin, gigoxin, or cyclosporine ^

Study Design

The drug-drug interaction potential of ledipasvir (LDV) in combination with vedroprevir (VDV) and tegobuvir (TGV) with pravastatin was evaluated.

Study Results

Co-administration of LDV/VDV/TGV and rosuvastatin resulted in a significant increase in Cmax and AUC by 1670% and 699%, respectively, for rosuvastatin.Co-administration of rosuvastatin with this combination is not recommended due to the increased risk of myopathy.

Study Conclusions

References

P German, Pang PS, L Fang, et al. Drug-drug interaction profile of the fixed dose combination tablet ledipasvir/sofosbuvir. American Association For The Study Of Liver Diseases. Boston, MA. ; 2014.